Restless Legs Syndrome News
Most Popular Restless Legs Syndrome Story
XenoPort meltdown triggers collateral damage at Depomed
The FDA's decision to reject a marketing application for a new restless leg syndrome therapy from XenoPort and GlaxoSmithKline triggered a 66 percent plunge in the smaller developer's share price... Read more...
Latest Headlines
- February 19, 2010
- November 10, 2008
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
